The Write-Off That Isn't

The write-off line in your denial report is not a measure of what payers owe you and will not pay. For most provider organizations, it is a measure of how many recoverable claims no one got around to fighting, and the dollar value sitting in that line belongs in the same CFO conversation as every other recoverable revenue metric the platform tracks. A KFF analysis of 2024 CMS Medicare Advantage data documents that 80.7% of prior authorization appeals were partially or fully overturned, a finding consistent across every year of data examined going back to 2019. The same analysis documents that only 11.5% of denied prior authorization requests were appealed in 2024. Those two numbers define a revenue problem that is operational in character, not clinical: the majority of prior authorization denials most organizations are writing off are denials they would win if they filed the appeal, and the payer is counting on the fact that they will not.

The financial consequence of that gap compounds in ways most CFOs and RCM directors are not measuring, in part because the write-off classification obscures what is actually happening. A practice carrying $200,000 in unappealed prior authorization denials annually, against an 80% overturn rate, is not managing an unrecoverable loss. It is absorbing a recoverable loss because the administrative cost and operational friction of appealing appears higher than the expected recovery on any individual claim. The CFO reviewing a consolidated denial report sees a write-off total; the CFO who has mapped the 80.7% overturn rate against that same figure sees an accounts receivable problem with a calculable recovery rate, and those are two materially different conversations to have with a board or a PE operating partner.

The reason most organizations arrive at the wrong answer is that the economic analysis defaults to the claim level rather than the portfolio level. The per-claim cost of assembling documentation and drafting an appeal letter is real, and on a $300 denied claim the math is close enough that many billing teams conclude the effort is not worth it. What that calculation misses is that the fixed cost of building payer-specific appeal templates, training staff on criteria-mapped documentation, and routing denials automatically into an appeal queue is spread across every claim the workflow touches, not assessed against each claim individually. Once the infrastructure is in place, the marginal cost of filing one additional appeal is the staff time to submit it, not the staff time to build it. The $300 claim that looked borderline as a standalone effort looks materially different when the template is built, the routing is automated, and the submission takes ten minutes. Assessed against a portfolio of 500 denied prior authorization claims per year at an average allowed amount of $400, an 80% overturn rate applied to a systematic workflow represents $160,000 in recoverable revenue against a workflow investment that is a fraction of that figure.

The KFF Medicare Advantage dataset is the most precisely sourced available because MA plans are required to report prior authorization outcomes publicly. The 11.5% appeal rate and 80.7% overturn rate it documents are not specific to Medicare Advantage as a plan type. Across every plan type where comparable data exists, the same structure appears: appeal rates are low, overturn rates are materially higher than most billing teams assume, and the space between them represents revenue being written off rather than recovered. A separate KFF analysis of ACA Marketplace plans documents an appeal rate under 1% for post-service claim denials against a 44% overturn rate. A Premier survey of commercial fully insured claims documents a 54.3% overturn rate across all denial categories. The CMS Interoperability and Prior Authorization Final Rule, CMS-0057-F, effective March 31, 2026, now requires Medicare Advantage organizations, Medicaid managed care plans, CHIP plans, and ACA marketplace issuers to publicly post prior authorization approval and denial rates, appeal outcomes, and average decision timeframes annually. For every plan type where public data now exists, the pattern holds: the overturn rate on appealed denials is high enough that the decision not to appeal is, in most organizations, a financial decision wearing the clothing of an administrative one.

For the CFO or PE operating partner who manages RCM as a financial output rather than a set of daily workflows, the practical implication is that the write-off total in the current denial report is not a settled number. A portion of it is recoverable this year, in this performance period, through a workflow change that does not require a technology platform investment to begin. The recoverable amount is calculable using data the practice already has: denied claim volume, average allowed amount by payer and procedure, and the applicable overturn rate from public CMS data. That calculation produces a specific figure the board can evaluate against the cost of building the systematic appeal workflow that captures it. Organizations recovering that revenue are not doing so through superior clinical documentation or more favorable payer relationships. They built a workflow that treats every denied claim as a filed appeal by default and made that the lowest-cost path rather than the highest.

The remainder of this series covers the mechanics of that workflow, the payer behavior that created the appeal barrier in the first place, the legal standards governing peer-to-peer review that most practices are not invoking, and what contract language can do where state law does not reach. Each of those pieces is actionable on its own. This one is the foundation: the revenue sitting in unappealed prior authorization denials is already in your aging report, already has a calculable dollar value, and the case for recovering it has been in the public record for years.